Navigation Links
Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation

MOUNTAIN VIEW, Calif., June 8, 2011 /PRNewswire/ -- Edison Pharmaceuticals, Inc. announced today the United States Food and Drug Administration has granted orphan drug designation to EPI-743 for treatment of inherited mitochondrial respiratory chain diseases. Today, these mitochondrial diseases affect an estimated 60,000 individuals.

The Orphan Drug Act, passed in 1982, provides incentives for companies to pursue treatments for diseases affecting fewer than 200,000 individuals in the United States. Such designation provides an accelerated review and a seven-year period of exclusivity upon FDA approval.

The FDA granted orphan drug designation to Edison's EPI-743 based on review of the application, which included clinical and pre-clinical data demonstrating a favorable efficacy and safety profile.

About Inherited Mitochondrial Disease

Inherited mitochondrial diseases are genetic disorders that share as a common link defects in how cells make and regulate energy. They can arise through defects in genes located in the nucleus or mitochondria. An estimated 2,000 defects in nuclear DNA and 200 defects in mitochondrial DNA have been identified that are pathogenic(1). Inherited mitochondrial diseases are clinically diverse and poorly understood. They can affect virtually any organ system in the body. As the brain and muscle tissue use an extraordinary amount of energy, they are dramatically affected by these disorders. Mitochondrial diseases often present with central nervous system manifestations, but they also result in a variety of other significant clinical signs that include diabetes, heart failure, liver failure, deafness, blindness, renal insufficiency, and muscle weakness and fatigue.

The incidence of mitochondrial disease is estimated at 1-5 in 10,000. However, this number may underestimate the true number of people with mitochondrial disease. While new genetic screening tools have made detection of mitochondrial disease possible, the majority of individuals with a clinical diagnosis of mitochondrial disease may not have a confirmatory genetic diagnosis. Some estimates place the number of clinically diagnosed mitochondrial disease patients without a genetic diagnosis– so called mitochondrial syndromes– at 10 times the incidence of genetically defined disease.

Science today is at the frontier of mitochondrial medicine. Certain diseases that previously lacked a known cause are now being defined as mitochondrial in etiology. It is possible that in the future mitochondrial disease will be implicated in additional diseases, such as in the biology of cancer.

Edison Pharmaceuticals

Edison Pharmaceuticals is a patient- and physician-founded company devoted to developing new medicines that will transform the lives of those diagnosed with rare and neglected diseases. Currently, the company is focused on inherited mitochondrial diseases for which there are no approved drugs. These conditions are life-threatening and highly debilitating. Edison's specialized skill set spans the discovery, development, and translation of redoxbased drugs.


SOURCE Edison Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Samsung Medison Pledges to Become a World-Class Medical Device Company
2. NOMAD by Aribex Receives Edison Best New Product Award
3. Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards
4. Osteotechs Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council
5. Zargis Medical Strikes Gold at 2010 Edison Awards
6. Orthocare Innovations Compas and Smart Pyramid Recognized at Edison Best New Product Awards
7. Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards
8. Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
9. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
10. Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at
11. Onyx Pharmaceuticals to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
Post Your Comments:
(Date:10/13/2015)... 2015 Attracting mid- to large-sized medical device companies ... Baltimore into a major medical device ... Maryland Technology Enterprise Institute (Mtech) . ... place to support innovation hubs and a thriving medical device ... "This study is important because we believe Baltimore ...
(Date:10/13/2015)... Fla. , Oct. 13, 2015   Vigilant ... of solutions that aid in the early detection and ... has awarded Vigilant,s founder and CEO, Matthew H.J. ... Year Award, which recognizes an entrepreneur who has made ... life sciences industry in the leadership of ...
(Date:10/13/2015)... DURHAM, N.C. , Oct. 13, 2015   ... from the DESSOLVE I and II trials of its ... MiStent SES ® ) were presented at the ... held in San Francisco , October ... in interventional cardiovascular medicine. MiStent SES was designed to ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... PhyMed Healthcare Group , a ... partnership with WPC Healthcare , a provider of predictive analytics solutions for ... into an aggregated data repository necessary to perform reporting and analytics on selected ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an article published ... that women who successfully lose weight with a bariatric procedure are much less likely ... The article notes that anywhere from 40 to 50 percent of all endometrial cancer ...
(Date:10/13/2015)... Laguna Hills, CA (PRWEB) , ... October 13, ... ... document management and workflow solutions, announced today their sponsorship of the Microsoft Dynamics ... in Reno-Tahoe, Nevada. AXUG Summit, GPUG Summit and NAVUG Summit are independent user ...
(Date:10/13/2015)... ... 2015 , ... Element Blue ™, a leading IT ... RightSensor™ LLC, an Internet of Things (IoT) hardware supplier that delivers custom and ... for customers requiring sensor hardware for critical data environments. , RightSensor™, working with ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a ... announced today a significant contract that will provide its award-winning private messaging solution ... on the growing success of its Relay program, IBX Wire™, which now has ...
Breaking Medicine News(10 mins):